



## Clinical trial results:

**An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N.**

### Summary

EudraCT number	2017-004040-38
Trial protocol	GB FR DE BE ES IT
Global end of trial date	09 November 2022

### Results information

Result version number	v1 (current)
This version publication date	20 July 2024
First version publication date	20 July 2024

### Trial information

#### Trial identification

Sponsor protocol code	SSCR105/NEAT33
-----------------------	----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05349838
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	NEAT ID Foundation
Sponsor organisation address	56 Rue des Colonies, Brussels, Belgium, 1000 Brussels
Public contact	WISARD Clinical Project Manager, Research Organisation KC, 0044 7376618244, WISARD@rokcservices.com
Scientific contact	Graeme Moyle, Chelsea and Westminster Hospital, 0044 020 7938 2355, geyyom@gmail.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 November 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 November 2022
Global end of trial reached?	Yes
Global end of trial date	09 November 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To compare efficacy of DTG/RPV combined tablet versus continued antiretroviral treatment regimen at 48 weeks in individuals with the K103N resistance mutation.

Protection of trial subjects:

Insurance was put in place to protect trial subjects.

Background therapy:

N/A

Evidence for comparator:

N/A

Actual start date of recruitment	15 October 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 22
Country: Number of subjects enrolled	United Kingdom: 52
Country: Number of subjects enrolled	Belgium: 9
Country: Number of subjects enrolled	France: 36
Country: Number of subjects enrolled	Germany: 10
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Italy: 10
Worldwide total number of subjects	140
EEA total number of subjects	88

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	125
From 65 to 84 years	15
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment began with first subject consented on 15-Oct-2018 and ended with last final subject enrolled on 10-Dec-2020. Subjects were recruited from sites in the following territories: UK, Spain, France, Belgium, Italy, Germany, Ireland.

### Pre-assignment

Screening details:

All subjects selected as potential suitable for the study were screened within a 30 days of the baseline visit. The purpose of the screening visits was to assess subjects for eligibility based on the eligibility criteria in the protocol. Screening data was entered into the eCRF by the study site staff and assessed by staff at the CRO.

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Arm A - Immediate switch

Arm description:

Participants randomised to this arm switch to Dolutegravir/Rilpivirine Fixed Dose Combination (Juluca) at baseline.

Arm type	Experimental
Investigational medicinal product name	Juluca (Dolutegravir and Rilpivirine Fixed Dose Combination)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

One combined Dolutegravir 50mg/Rilpivirine 25mg Fixed Dose Combination tablet taken orally once daily for 96 weeks.

<b>Arm title</b>	Arm B - Deferred switch
------------------	-------------------------

Arm description:

Subjects randomised to this arm continued on their current antiretroviral treatment until week 48 and then switched to the study IMP. They remained on the study IMP until week 96.

Arm type	Active comparator
Investigational medicinal product name	Juluca (Dolutegravir and Rilpivirine Fixed Dose Combination)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

One combined Dolutegravir 50mg/Rilpivirine 25mg Fixed Dose Combination tablet taken orally once daily from week 48 to week 96.

<b>Number of subjects in period 1</b>	Arm A - Immediate switch	Arm B - Deferred switch
Started	95	45
Completed	83	37
Not completed	12	8
Consent withdrawn by subject	2	3
Physician decision	1	1
Adverse event, non-fatal	3	1
Virological Failure	1	2
Patient relocation to another country	2	-
Lost to follow-up	1	1
Concomitant Medication	2	-

## Baseline characteristics

### Reporting groups

Reporting group title	Arm A - Immediate switch
-----------------------	--------------------------

Reporting group description:

Participants randomised to this arm switch to Dolutegravir/Rilpivirine Fixed Dose Combination (Juluca) at baseline.

Reporting group title	Arm B - Deferred switch
-----------------------	-------------------------

Reporting group description:

Subjects randomised to this arm continued on their current antiretroviral treatment until week 48 and then switched to the study IMP. They remained on the study IMP until week 96.

Reporting group values	Arm A - Immediate switch	Arm B - Deferred switch	Total
Number of subjects	95	45	140
Age categorical			
Units: Subjects			
Adults (18-64 years)	84	42	126
From 65-84 years	11	3	14
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	16	10	26
Male	79	35	114
Ethnicity			
subject ethnicity at baseline			
Units: Subjects			
White caucasian	69	29	98
White mixed	2	1	3
Asian	4	0	4
Black	7	7	14
African	3	3	6
Caribbean	1	1	2
Other	9	4	13
Time since HIV diagnosis (years)			
Time since HIV diagnosis (years)			
Units: Years			
median	17.1	22.4	
inter-quartile range (Q1-Q3)	7.3 to 26.3	13.1 to 26.5	-
Duration of Antiretroviral Treatment (ART) (years)			
Duration of Antiretroviral Treatment (ART) (years)			
Units: Years			
median	16	17.7	
inter-quartile range (Q1-Q3)	6.3 to 23	10.5 to 23	-

### Subject analysis sets

Subject analysis set title	All subjects
----------------------------	--------------

Subject analysis set type	Full analysis
---------------------------	---------------

<b>Reporting group values</b>	All subjects		
Number of subjects	140		
Age categorical			
Units: Subjects			
Adults (18-64 years)	126		
From 65-84 years	14		
85 years and over	0		
Gender categorical			
Units: Subjects			
Female	26		
Male	114		
Ethnicity			
subject ethnicity at baseline			
Units: Subjects			
White caucasian	98		
White mixed	3		
Asian	4		
Black	14		
African	6		
Caribbean	2		
Other	13		
Time since HIV diagnosis (years)			
Time since HIV diagnosis (years)			
Units: Years			
median	19.7		
inter-quartile range (Q1-Q3)	8.8 to 26.4		
Duration of Antiretroviral Treatment (ART) (years)			
Duration of Antiretroviral Treatment (ART) (years)			
Units: Years			
median	16.5		
inter-quartile range (Q1-Q3)	7.3 to 23		

## End points

### End points reporting groups

Reporting group title	Arm A - Immediate switch
Reporting group description: Participants randomised to this arm switch to Dolutegravir/Rilpivirine Fixed Dose Combination (Juluca) at baseline.	
Reporting group title	Arm B - Deferred switch
Reporting group description: Subjects randomised to this arm continued on their current antiretroviral treatment until week 48 and then switched to the study IMP. They remained on the study IMP until week 96.	
Subject analysis set title	All subjects
Subject analysis set type	Full analysis
Subject analysis set description: Analysis on Arm A Immediate switch and Arm B Deferred switch	

### Primary: Virological Response at Week 48

End point title	Virological Response at Week 48
End point description:	
End point type	Primary
End point timeframe: Week 48	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: Percentage				
number (confidence interval 95%)				
HIV RNA <50 copies/mL	88.4 (80.2 to 94.1)	88.9 (75.9 to 96.3)		
HIV RNA ≥50 copies/mL	3.2 (0.7 to 9.0)	2.2 (0.1 to 11.8)		
No virologic data at week 48	8.4 (3.7 to 15.9)	8.9 (2.5 to 21.2)		

Attachments (see zip file)	FDA Snapshot Week 48.png
----------------------------	--------------------------

### Statistical analyses

Statistical analysis title	ITT FDA Snapshot
Statistical analysis description: Proportion of participants with HIV-RNA <50 copies/mL at week 48, with the ITT FDA Snapshot method	
Comparison groups	Arm A - Immediate switch v Arm B - Deferred switch



Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	< 0.1
Method	Regression, Logistic
Parameter estimate	ITT FDA Snapshot
Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

Notes:

[1] - The two-sided 95% confidence interval of the difference in therapeutic success rate will be calculated.

The effect of study treatment will also be assessed in the mITT population using logistic regression model with treatment group adjusted for the presence of M184V mutation at baseline and CD4 count at baseline (above versus below 350 cells/ $\mu$ L) as well as all baseline variables potentially associated with the outcome, with univariable P-value <0.10.

### Secondary: Change from baseline in CD4 cell count

End point title	Change from baseline in CD4 cell count
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48, Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: count/mm <sup>3</sup>				
arithmetic mean (standard error)				
Change from baseline to week 48	-31.7 ( $\pm$ 34.8)	9.2 ( $\pm$ 51)		
Change from week 48 to week 96	27.3 ( $\pm$ 36.3)	-9.8 ( $\pm$ 55.3)		
Change from baseline to week 96	-4.4 ( $\pm$ 47.1)	-0.7 ( $\pm$ 71.0)		

<b>Attachments (see zip file)</b>	Change from BL in CD4 cell count.png
-----------------------------------	--------------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in CD8 cell count

End point title	Change from baseline in CD8 cell count
-----------------	--

End point description:

End point type	Secondary
End point timeframe:	
Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: count/mm3				
arithmetic mean (standard error)				
Change from baseline to week 48	-58.8 (± 41.3)	9.7 (± 60.4)		
Change from week 48 to week 96	-5.7 (± 43.2)	-55.8 (± 66.6)		
Change from baseline to week 96	-64.5 (± 53.4)	-46.1 (± 81.3)		

<b>Attachments (see zip file)</b>	Change from BL in CD8 cell count.png
-----------------------------------	--------------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in CD4/CD8 ratio

End point title	Change from baseline in CD4/CD8 ratio
End point description:	

End point type	Secondary
End point timeframe:	
Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: Cd4/Cd8 ratio				
arithmetic mean (standard error)				
Change from baseline to week 48	0.03 (± 0.06)	0.02 (± 0.09)		
Change from week 48 to week 96	0.04 (± 0.06)	0 (± 0.10)		
Change from baseline to week 96	0.07 (± 0.08)	0.01 (± 0.13)		

<b>Attachments (see zip file)</b>	Change from BL in CD4 CD8 ratio.png
-----------------------------------	-------------------------------------

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in body weight

End point title	Change from baseline in body weight
-----------------	-------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: Body weight, kg				
arithmetic mean (standard error)				
Change from baseline to week 48	0.7 (± 2.1)	1.3 (± 3.1)		
Change from week 48 to week 96	1.7 (± 2.2)	1.3 (± 3.4)		
Change from baseline to week 96	2.4 (± 3.0)	2.6 (± 4.5)		

<b>Attachments (see zip file)</b>	Change from BL in body weight.png
-----------------------------------	-----------------------------------

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in BMI

End point title	Change from baseline in BMI
-----------------	-----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: kg/m2				
arithmetic mean (standard error)				
Change from baseline to week 48	0.3 (± 0.6)	0.6 (± 0.9)		
Change from week 48 to week 96	0.5 (± 0.7)	0.3 (± 1.0)		
Change from baseline to week 96	0.8 (± 0.9)	0.9 (± 1.3)		

<b>Attachments (see zip file)</b>	Change from BL in BMI.png
-----------------------------------	---------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in hsCRP

End point title	Change from baseline in hsCRP
End point description:	
End point type	Secondary
End point timeframe:	Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	24		
Units: mg/L				
arithmetic mean (standard error)				
Change from baseline to week 48	0.8 (± 1.2)	-1.3 (± 1.8)		
Change from week 48 to week 96	0.5 (± 1.2)	-0.9 (± 1.9)		
Change from baseline to week 96	1.3 (± 1.4)	-2.2 (± 2.1)		

<b>Attachments (see zip file)</b>	Change from BL in hsCRP.png
-----------------------------------	-----------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Systolic Blood Pressure

End point title	Change from baseline in Systolic Blood Pressure
-----------------	---

End point description:

End point type	Secondary
End point timeframe:	
Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	45		
Units: mmHg				
arithmetic mean (standard error)				
Change from baseline to week 48	-1.4 (± 2.2)	4.9 (± 3.3)		
Change from week 48 to week 96	-0.1 (± 2.3)	5.6 (± 3.6)		
Change from baseline to week 96	-1.5 (± 2.7)	10.5 (± 4.1)		

Attachments (see zip file)	Change from BL in systolic blood pressure.png
----------------------------	---

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Diastolic Blood Pressure

End point title	Change from baseline in Diastolic Blood Pressure
End point description:	

End point type	Secondary
End point timeframe:	
Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: mmHg				
arithmetic mean (standard error)				
Change from baseline to week 48	0.2 (± 1.5)	3.1 (± 2.2)		
Change from week 48 to week 96	-0.7 (± 1.6)	0.8 (± 2.4)		
Change from baseline to week 96	-0.5 (± 1.8)	4.0 (± 2.7)		

<b>Attachments (see zip file)</b>	Change from BL in diastolic blood pressure.png
-----------------------------------	--

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Pulse rate

End point title	Change from baseline in Pulse rate
-----------------	------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: Pulse rate				
arithmetic mean (standard error)				
Change from baseline to week 48	2.1 (± 1.6)	2.7 (± 2.4)		
Change from week 48 to week 96	-2.5 (± 1.8)	-1.5 (± 2.6)		
Change from baseline to week 96	-0.4 (± 2.0)	1.2 (± 2.9)		

<b>Attachments (see zip file)</b>	Change from BL in pulse.png
-----------------------------------	-----------------------------

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Red blood cells

End point title	Change from baseline in Red blood cells
-----------------	---

End point description:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	45		
Units: 10 <sup>12</sup> /L				
arithmetic mean (standard error)				
Change from baseline to week 48	0.20 (± 0.06)	-0.07 (± 0.09)		
Change from week 48 to week 96;	-0.02 (± 0.07)	0.19 (± 0.10)		
Change from baseline to week 96	0.17 (± 0.09)	0.12 (± 0.13)		

<b>Attachments (see zip file)</b>	Change from BL in RBC.png
-----------------------------------	---------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in White blood cells

End point title	Change from baseline in White blood cells
End point description:	
End point type	Secondary
End point timeframe:	Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: 10 <sup>12</sup> /L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.08 (± 0.26)	-0.06 (± 0.38)		
Change from week 48 to week 96	0.09 (± 0.27)	-0.03 (± 0.41)		
Change from baseline to week 96	0.01 (± 0.34)	-0.09 (± 0.51)		

<b>Attachments (see zip file)</b>	Change from BL in WBC.png
-----------------------------------	---------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Platelet counts

End point title	Change from baseline in Platelet counts
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: 10 <sup>9</sup> /L				
arithmetic mean (standard error)				
Change from baseline to week 48	3.4 (± 8.2)	-2.6 (± 12.1)		
Change from week 48 to week 96	0.6 (± 8.6)	9.3 (± 13.1)		
Change from baseline to week 96	4.0 (± 11.1)	6.7 (± 16.8)		

<b>Attachments (see zip file)</b>	Change from BL in Platelet count.png
-----------------------------------	--------------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Haemoglobin

End point title	Change from baseline in Haemoglobin
-----------------	-------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: g/dL				
arithmetic mean (standard error)				
Change from baseline to week 48	0.1 (± 0.2)	0 (± 0.3)		
Change from week 48 to week 96	0 (± 0.2)	0.2 (± 0.3)		
Change from baseline to week 96	0.1 (± 0.3)	0.2 (± 0.4)		



<b>Attachments (see zip file)</b>	Change from BL in haemoglobin.png
-----------------------------------	-----------------------------------

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Sodium

End point title	Change from baseline in Sodium
-----------------	--------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	0.3 (± 0.3)	-0.8 (± 0.4)		
Change from week 48 to week 96	-0.5 (± 0.3)	0.3 (± 0.4)		
Change from baseline to week 96	-0.2 (± 0.3)	-0.5 (± 0.5)		

<b>Attachments (see zip file)</b>	Change from BL in sodium.png
-----------------------------------	------------------------------

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in ALT

End point title	Change from baseline in ALT
-----------------	-----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	45		
Units: U/L				
arithmetic mean (standard error)				
Change from baseline to week 48	2.4 (± 3.2)	-0.6 (± 4.7)		
Change from week 48 to week 96	-0.7 (± 3.4)	1.1 (± 5.1)		
Change from baseline to week 96	1.8 (± 3.7)	0.6 (± 5.6)		

<b>Attachments (see zip file)</b>	Change from BL in ALT.png
-----------------------------------	---------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Total Bilirubin

End point title	Change from baseline in Total Bilirubin
End point description:	
End point type	Secondary
End point timeframe:	Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: umol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.6 (± 1.4)	-1.9 (± 2.0)		
Change from week 48 to week 96	-1.3 (± 1.4)	-2.2 (± 2.2)		
Change from baseline to week 96	-1.9 (± 1.4)	-4.1 (± 2.1)		

<b>Attachments (see zip file)</b>	Change from BL in bilirubin.png
-----------------------------------	---------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Glucose

End point title	Change from baseline in Glucose
-----------------	---------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	43		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.15 (± 0.16)	-0.06 (± 0.23)		
Change from week 48 to week 96	0.09 (± 0.17)	-0.11 (± 0.25)		
Change from baseline to week 96	-0.06 (± 0.21)	-0.17 (± 0.31)		

<b>Attachments (see zip file)</b>	Change from BL in glucose.png
-----------------------------------	-------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Total Cholesterol

End point title	Change from baseline in Total Cholesterol
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	45		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.09 (± 0.14)	0.05 (± 0.20)		
Change from week 48 to week 96	0.02 (± 0.15)	-0.19 (± 0.22)		
Change from baseline to week 96	-0.07 (± 0.18)	-0.13 (± 0.27)		

<b>Attachments (see zip file)</b>	Change from BL in total cholesterol.png
-----------------------------------	---

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in HDL cholesterol

End point title	Change from baseline in HDL cholesterol
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	44		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	0.06 ( $\pm$ 0.05)	0.03 ( $\pm$ 0.07)		
Change from week 48 to week 96	-0.03 ( $\pm$ 0.05)	0.01 ( $\pm$ 0.08)		
Change from baseline to week 96	0.03 ( $\pm$ 0.06)	0.04 ( $\pm$ 0.10)		

<b>Attachments (see zip file)</b>	Change from BL in HDL cholesterol.png
-----------------------------------	---------------------------------------

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in LDL cholesterol

End point title	Change from baseline in LDL cholesterol
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	42		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.05 (± 0.12)	0 (± 0.18)		
Change from week 48 to week 96	0.02 (± 0.12)	-0.14 (± 0.19)		
Change from baseline to week 96	-0.02 (± 0.15)	-0.14 (± 0.23)		

<b>Attachments (see zip file)</b>	Change from BL in LDL cholesterol.png
-----------------------------------	---------------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Triglycerides

End point title	Change from baseline in Triglycerides
End point description:	
End point type	Secondary
End point timeframe:	Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	45		
Units: mmol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.26 (± 0.15)	-0.02 (± 0.22)		
Change from week 48 to week 96	0.14 (± 0.15)	-0.16 (± 0.23)		
Change from baseline to week 96	-0.12 (± 0.18)	-0.18 (± 0.27)		

<b>Attachments (see zip file)</b>	Change from BL in triglycerides.png
-----------------------------------	-------------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Creatinine

End point title	Change from baseline in Creatinine
-----------------	------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	44		
Units: umol/L				
arithmetic mean (standard error)				
Change from baseline to week 48	3.0 (± 2.3)	0.3 (± 3.4)		
Change from week 48 to week 9	0.3 (± 2.4)	5.5 (± 3.7)		
Change from baseline to week 96	3.3 (± 3.1)	5.8 (± 4.7)		

<b>Attachments (see zip file)</b>	Change from BL in creatinine.png
-----------------------------------	----------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Creatinine clearance

End point title	Change from baseline in Creatinine clearance
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	44		
Units: mL/min				
arithmetic mean (standard error)				
Change from baseline to week 48	-1.7 (± 2.2)	-1.3 (± 3.3)		
Change from week 48 to week 96	-1.2 (± 2.3)	-3.4 (± 3.6)		
Change from baseline to week 96	-2.9 (± 2.8)	-4.7 (± 4.2)		

<b>Attachments (see zip file)</b>	Change from BL in creatinine clearance.png
-----------------------------------	--

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in ALP

End point title	Change from baseline in ALP
-----------------	-----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

<b>End point values</b>	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: U/L				
arithmetic mean (standard error)				
Change from baseline to week 48	-5.3 (± 3.0)	-1.5 (± 4.3)		
Change from week 48 to week 96	3.1 (± 3.1)	-2.5 (± 4.7)		
Change from baseline to week 96	-2.2 (± 4.0)	-4.0 (± 6.0)		

<b>Attachments (see zip file)</b>	Change from BL in ALP.png
-----------------------------------	---------------------------

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in QOL Health status score

End point title	Change from baseline in QOL Health status score
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	93	43		
Units: Health status score				
arithmetic mean (standard error)				
Change from baseline to week 48	1.7 (± 2.9)	6.3 (± 4.3)		
Change from week 48 to week 96	-2.0 (± 3.0)	-7.2 (± 4.6)		
Change from baseline to week 96	-0.3 (± 3.3)	-0.9 (± 5.0)		

<b>Attachments (see zip file)</b>	Change from BL in QoL Health score.png
-----------------------------------	--

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in patients' satisfaction

End point title	Change from baseline in patients' satisfaction
End point description:	
End point type	Secondary
End point timeframe:	Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	45		
Units: Global satisfaction score				
arithmetic mean (standard error)				
Change from baseline to week 48	1.6 (± 0.6)	0.7 (± 0.9)		
Change from week 48 to week 96	0.2 (± 0.6)	0.4 (± 1.0)		
Change from baseline to week 96	1.8 (± 0.7)	1.1 (± 1.1)		

<b>Attachments (see zip file)</b>	Change from BL in patient satisfaction.png
-----------------------------------	--

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from baseline in Global Pittsburgh Sleep Quality Index (PSQI) score



End point title	Change from baseline in Global Pittsburgh Sleep Quality Index (PSQI) score
End point description:	
End point type	Secondary
End point timeframe:	
Change from baseline to week 48; Change from week 48 to week 96; Change from baseline to week 96	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	40		
Units: Global PSQI Score				
arithmetic mean (standard error)				
Change from baseline to week 48	-0.1 (± 0.3)	-0.7 (± 0.5)		
Change from week 48 to week 96	0 (± 0.3)	-0.5 (± 0.5)		
Change from baseline to week 96	-0.1 (± 0.3)	-1.2 (± 0.5)		

<b>Attachments (see zip file)</b>	Change from BL in PSQI.png
-----------------------------------	----------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adverse events (AEs) from baseline to week 48

End point title	Number of participants with adverse events (AEs) from baseline to week 48
End point description:	
End point type	Secondary
End point timeframe:	
Baseline to week 48	

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: Number				
number (not applicable)				
Any AEs	78	33		
Grade 1	61	25		
Grade 2	43	13		

Grade 3-4	7	2		
Drug related AEs	22	0		
Drug related grade 3-4 AEs	1	0		
AE leading to the study drugs interruption	4	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adverse events (AEs) Week 48 to week 96

End point title	Number of participants with adverse events (AEs) Week 48 to week 96
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48 to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87	34		
Units: Number				
number (not applicable)				
Any AEs	54	28		
Grade 1	36	18		
Grade 2	20	12		
Grade 3-4	5	5		
Drug related AEs	1	5		
Drug related grade 3-4 AEs	0	0		
AEs leading to the study drugs interruption	1	2		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of drug-drug interactions

End point title	Number of drug-drug interactions <sup>[2]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to week 96

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Both arms reported separately due to different timepoints reported.

End point values	Arm A - Immediate switch			
Subject group type	Reporting group			
Number of subjects analysed	95			
Units: Number				
Baseline	90			
Week 24	88			
Week 48	86			
Week 96	81			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with Adverse Events (AEs) from baseline to week 48

End point title	Number of participants with Adverse Events (AEs) from baseline to week 48
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to week 48

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: number				
Any AEs	78	33		
Grade 1	61	25		
Grade 2	43	13		
Grade 3-4	7	2		
Drug related AEs	22	0		
Drug related grade 3-4 AEs	1	0		
AEs leading to the study drug interruption	4	0		
Missing Grade	6	1		
Serious Adverse Events (SAEs)	4	2		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adverse events (AEs) from week 48 to week 96

End point title	Number of participants with adverse events (AEs) from week 48 to week 96
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

week 48 to week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87	40		
Units: Number				
Any AEs	54	28		
Grade 1	36	18		
Grade 2	20	12		
Grade 3-4	5	5		
Drug related AEs	1	5		
Drug related grade 3-4 AEs	0	0		
AEs leading to the study drugs interruption	1	2		
Missing Grade	7	0		
Serious Adverse Events (SAEs)	5	1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Virological Response at Week 96

End point title	Virological Response at Week 96
-----------------	---------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 96

End point values	Arm A - Immediate switch	Arm B - Deferred switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	95	45		
Units: Percentage				
number (confidence interval 95%)				
HIV RNA <50 copies/mL	84.2 (75.3 to 90.9)	73.3 (58.1 to 85.4)		
HIV RNA =>50 copies/mL	5.3 (1.7 to 11.9)	6.7 (1.4 to 18.3)		
No virologic data at week 96	10.5 (5.2 to 18.5)	20 (9.6 to 34.6)		

Attachments (see zip file)	FDA Snapshot Week 96.png
----------------------------	--------------------------

## Statistical analyses

Statistical analysis title	ITT FDA Snapshot
----------------------------	------------------

Statistical analysis description:

Proportion of participants with HIV-RNA <50 copies/mL at week 96, with the ITT FDA Snapshot method

Comparison groups	Arm B - Deferred switch v Arm A - Immediate switch
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	< 0.1
Method	Regression, Logistic
Parameter estimate	ITT FDA Snapshot
Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

Notes:

[3] - The two-sided 95% confidence interval of the difference in therapeutic success rate will be calculated.

The effect of study treatment will also be assessed in the mITT population using logistic regression model with treatment group adjusted for the presence of M184V mutation at baseline and CD4 count at baseline (above versus below 350 cells/ $\mu$ L) as well as all baseline variables potentially associated with the outcome, with univariable P-value <0.10.

## Secondary: Number of drug-drug interactions

End point title	Number of drug-drug interactions <sup>[4]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to week 96

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Both arms reported separately due to different timepoints reported.

<b>End point values</b>	Arm B - Deferred switch			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number				
Baseline	45			
Week 48	39			
Week 96	38			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

The adverse event reporting period will be from consent until the subject's final study visit (I.e. follow-up visit or end of trial visit).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23

### Reporting groups

Reporting group title	Arm A - Immediate switch
-----------------------	--------------------------

Reporting group description:

Participants randomised to this arm switch to Dolutegravir/Rilpivirine Fixed Dose Combination (Juluca) at baseline.

Reporting group title	Arm B - Deferred switch
-----------------------	-------------------------

Reporting group description:

Subjects randomised to this arm continued on their current antiretroviral treatment until week 48 and then switched to the study IMP. They remained on the study IMP until week 96.

Serious adverse events	Arm A - Immediate switch	Arm B - Deferred switch	
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 95 (10.53%)	4 / 45 (8.89%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Meningioma			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile neoplasm			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			

alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Patella fracture			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Prostatectomy			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
pachymeningitis			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Pancreatitis			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicidal ideation			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	



Infections and infestations Pneumonia bacterial subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 95 (1.05%) 0 / 1 0 / 0	0 / 45 (0.00%) 0 / 0 0 / 0	
covid19 pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 95 (0.00%) 0 / 0 0 / 0	1 / 45 (2.22%) 0 / 1 0 / 0	
Legionella infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 95 (1.05%) 0 / 1 0 / 0	0 / 45 (0.00%) 0 / 0 0 / 0	
Pilonidal cyst subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 95 (1.05%) 0 / 1 0 / 0	0 / 45 (0.00%) 0 / 0 0 / 0	
Atypical mycobacterial infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 95 (0.00%) 0 / 0 0 / 0	1 / 45 (2.22%) 0 / 1 0 / 0	
Postoperative wound infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 95 (1.05%) 0 / 1 0 / 0	0 / 45 (0.00%) 0 / 0 0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Arm A - Immediate switch	Arm B - Deferred switch	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	84 / 95 (88.42%)	38 / 45 (84.44%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anogenital warts			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haemangioma of skin</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Uterine leiomyoma</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Skin papilloma</p> <p>alternative dictionary used: MedDRA 24</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 95 (1.05%)</p> <p>1</p> <p>0 / 95 (0.00%)</p> <p>0</p> <p>1 / 95 (1.05%)</p> <p>1</p> <p>0 / 95 (0.00%)</p> <p>0</p>	<p>1 / 45 (2.22%)</p> <p>1</p> <p>1 / 45 (2.22%)</p> <p>1</p> <p>0 / 45 (0.00%)</p> <p>0</p> <p>1 / 45 (2.22%)</p> <p>1</p>	
<p>Vascular disorders</p> <p>Hypertension</p> <p>alternative dictionary used: MedDRA 24</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diastolic hypertension</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Systolic Hypertension</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 95 (6.32%)</p> <p>6</p> <p>1 / 95 (1.05%)</p> <p>1</p> <p>1 / 95 (1.05%)</p> <p>1</p>	<p>1 / 45 (2.22%)</p> <p>1</p> <p>0 / 45 (0.00%)</p> <p>0</p> <p>0 / 45 (0.00%)</p> <p>0</p>	
<p>Surgical and medical procedures</p> <p>Foot operation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Skin neoplasm excision</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Acrochordon excision</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Sympathectomy</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 95 (1.05%)</p> <p>2</p> <p>1 / 95 (1.05%)</p> <p>1</p> <p>0 / 95 (0.00%)</p> <p>0</p> <p>1 / 95 (1.05%)</p> <p>1</p>	<p>0 / 45 (0.00%)</p> <p>0</p> <p>0 / 45 (0.00%)</p> <p>0</p> <p>1 / 45 (2.22%)</p> <p>1</p> <p>0 / 45 (0.00%)</p> <p>0</p>	

Nasal operation			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Pain			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Chest pain			
subjects affected / exposed	4 / 95 (4.21%)	0 / 45 (0.00%)	
occurrences (all)	4	0	
Discomfort			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Face oedema			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	5 / 95 (5.26%)	0 / 45 (0.00%)	
occurrences (all)	5	0	
Influenza like illness			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	0 / 95 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Energy increased			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Oedema peripheral			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Ulcer			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Chills			

subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1	
Mass subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Vaccination site pain alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Ill-defined disorder subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1	
Inflammation subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Asthenia alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	3 / 95 (3.16%) 3	0 / 45 (0.00%) 0	
Fatigue alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	3 / 95 (3.16%) 3	1 / 45 (2.22%) 1	
Immune system disorders Hypersensitivity alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	2 / 95 (2.11%) 2	0 / 45 (0.00%) 0	
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Social circumstances Disease risk factor subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Reproductive system and breast			

disorders			
Benign Prostatic Hyperplasia			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Menstrual disorder			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Breast pain			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Prostatitis			
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Genital lesion			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Rhinitis allergic			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Asthma			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	2	2	
Bronchial disorder			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Cough			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	3 / 95 (3.16%)	1 / 45 (2.22%)	
occurrences (all)	3	1	
Dyspnoea			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Dyspnoea exertional			

subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Nasal congestion			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 95 (1.05%)	2 / 45 (4.44%)	
occurrences (all)	1	2	
COVID-19			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Aggression			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Anxiety			
subjects affected / exposed	3 / 95 (3.16%)	2 / 45 (4.44%)	
occurrences (all)	3	2	
Depression			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Stress			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Insomnia			
subjects affected / exposed	8 / 95 (8.42%)	1 / 45 (2.22%)	
occurrences (all)	8	1	
Loss of libido			
alternative dictionary used: MedDRA 24			

subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Mental disorder			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Sleep disorder			
subjects affected / exposed	3 / 95 (3.16%)	1 / 45 (2.22%)	
occurrences (all)	3	1	
Abnormal dreams			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	4 / 95 (4.21%)	1 / 45 (2.22%)	
occurrences (all)	4	1	
Depressed mood			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Investigations			
Glomerular filtration rate abnormal			
subjects affected / exposed	0 / 95 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Blood pressure systolic increased			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Creatinine renal clearance decreased			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Blood pressure diastolic increased			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Glucose urine present			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	

Blood cholesterol increased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Red blood cell analysis abnormal alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Blood immunoglobulin M decreased subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Viral load increased subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1
Blood bilirubin subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Pathology test alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Mean cell haemoglobin decreased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Blood phosphorus decreased subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1
Vitamin D decreased subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Alanine aminotransferase increased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	8 / 95 (8.42%) 8	0 / 45 (0.00%) 0



Blood pressure increased subjects affected / exposed occurrences (all)	3 / 95 (3.16%) 3	0 / 45 (0.00%) 0
Blood bilirubin increased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Blood creatinine decreased subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1
Biopsy kidney subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Body temperature subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Transaminases increased subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Urine analysis abnormal subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	2 / 95 (2.11%) 2	0 / 45 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1
Blood creatine phosphokinase increased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	4 / 95 (4.21%) 4	2 / 45 (4.44%) 5

Blood creatinine increased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	5 / 95 (5.26%) 5	0 / 45 (0.00%) 0	
Glomerular filtration rate decreased alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	4 / 95 (4.21%) 4	2 / 45 (4.44%) 2	
Injury, poisoning and procedural complications			
Arthropod bite subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Exposure to communicable disease subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Dislocation of vertebra subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Limb injury subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1	
Neck injury subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Ligament sprain subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Phlebitis subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Procedural pain subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Contusion alternative dictionary used: MedDRA 24			

subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Soft tissue injury subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Epicondylitis subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Joint injury subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Cardiac disorders Myocardial ischaemia subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Left ventricular hypertrophy subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Palpitations subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	2 / 45 (4.44%) 2	
Nervous system disorders Radiculitis brachial alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Dizziness subjects affected / exposed occurrences (all)	2 / 95 (2.11%) 2	0 / 45 (0.00%) 0	
Epilepsy subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Memory impairment subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
headache			

alternative dictionary used: MedDRA 24			
subjects affected / exposed	16 / 95 (16.84%)	2 / 45 (4.44%)	
occurrences (all)	21	2	
lethargy			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Anosmia			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Ageusia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Migraine			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	3	0	
Sciatica			
subjects affected / exposed	2 / 95 (2.11%)	2 / 45 (4.44%)	
occurrences (all)	2	2	
Restless legs syndrome			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	3	0	
Lymphadenopathy			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Lymphopenia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Polycythaemia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			

Tinnitus subjects affected / exposed occurrences (all)	2 / 95 (2.11%) 2	0 / 45 (0.00%) 0	
Vertigo subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1	
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Visual impairment alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Gastrointestinal disorders abdominal pain subjects affected / exposed occurrences (all)	3 / 95 (3.16%) 3	1 / 45 (2.22%) 1	
Anal fissure subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
anal fistula subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Abdominal distension subjects affected / exposed occurrences (all)	2 / 95 (2.11%) 2	1 / 45 (2.22%) 1	
constipation alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	6 / 95 (6.32%) 7	0 / 45 (0.00%) 0	
Diarrhoea			

subjects affected / exposed	6 / 95 (6.32%)	4 / 45 (8.89%)
occurrences (all)	6	4
Jejunal ulcer		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Dry mouth		
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)
occurrences (all)	2	0
Steatorrhoea		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
flatulence		
subjects affected / exposed	3 / 95 (3.16%)	0 / 45 (0.00%)
occurrences (all)	3	0
gastrointestinal infection		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Haemorrhoids		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	4 / 95 (4.21%)	0 / 45 (0.00%)
occurrences (all)	4	0
Dyspepsia		
subjects affected / exposed	3 / 95 (3.16%)	2 / 45 (4.44%)
occurrences (all)	3	2
Eructation		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Lip pain		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Odynophagia		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	2 / 45 (4.44%)
occurrences (all)	1	2

oesophagitis			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Proctalgia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Proctitis			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Abdominal pain upper			
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Toothache			
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Abdominal discomfort			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Gastrointestinal disorder			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Nausea			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Proctitis gonococcal			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			

Alopecia areata		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Blister		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Skin reaction		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Eczema		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	4	0
Onychomycosis		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Pruritus		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)
occurrences (all)	2	1
Hyperkeratosis		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Intertrigo		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Dermatitis		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Skin lesion		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	2	0
Rash		



subjects affected / exposed	5 / 95 (5.26%)	0 / 45 (0.00%)	
occurrences (all)	12	0	
Seborrheic Dermatitis			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Alopecia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Cellulitis			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
ALBUMINURIA			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
dysuria			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Focal segmental glomerulosclerosis			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Nocturia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Chromaturia			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Pollakiuria			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
renal colic			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Urge incontinence			

subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Urinary incontinence			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Proteinuria			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Calculus bladder			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Muscle spasms			
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Periarthritis			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Bursitis			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Neck pain			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	2 / 45 (4.44%)	
occurrences (all)	1	2	
Limb discomfort			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Arthralgia			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	5 / 95 (5.26%)	2 / 45 (4.44%)	
occurrences (all)	5	2	
Pain in extremity			

subjects affected / exposed	3 / 95 (3.16%)	3 / 45 (6.67%)
occurrences (all)	3	3
Back pain		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	4 / 95 (4.21%)	0 / 45 (0.00%)
occurrences (all)	4	0
Myalgia		
subjects affected / exposed	5 / 95 (5.26%)	1 / 45 (2.22%)
occurrences (all)	5	1
Muscle atrophy		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Musculoskeletal pain		
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)
occurrences (all)	2	2
Osteoarthritis		
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)
occurrences (all)	1	1
Osteoporosis		
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)
occurrences (all)	1	1
Plantar fasciitis		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Muscle strain		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Tendonitis		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Osteopenia		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)
occurrences (all)	1	1

Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Joint swelling alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Tenosynovitis subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Infections and infestations			
Abscess alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Muscle abscess subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Cystitis subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Amoebiasis subjects affected / exposed occurrences (all)	0 / 95 (0.00%) 0	1 / 45 (2.22%) 1	
Genital herpes alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	0 / 45 (0.00%) 0	
Bronchitis alternative dictionary used: MedDRA 24 subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	2 / 45 (4.44%) 2	
Lower respiratory tract infection subjects affected / exposed occurrences (all)	1 / 95 (1.05%) 1	1 / 45 (2.22%) 1	
Chlamydial infection			

subjects affected / exposed	4 / 95 (4.21%)	2 / 45 (4.44%)
occurrences (all)	6	2
Influenza		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)
occurrences (all)	2	0
Nasopharyngitis		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	6 / 95 (6.32%)	5 / 45 (11.11%)
occurrences (all)	8	7
Rhinitis		
subjects affected / exposed	5 / 95 (5.26%)	1 / 45 (2.22%)
occurrences (all)	5	1
folliculitis		
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)
occurrences (all)	1	1
Fungal skin infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Fungal infection		
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)
occurrences (all)	3	0
Gastroenteritis		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)
occurrences (all)	2	1
Gingivitis		
subjects affected / exposed	2 / 95 (2.11%)	0 / 45 (0.00%)
occurrences (all)	2	0
Gonorrhoea		
subjects affected / exposed	4 / 95 (4.21%)	1 / 45 (2.22%)
occurrences (all)	4	2
Oropharyngeal gonococcal infection		
alternative dictionary used: MedDRA 24		

subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Gingival abscess		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Helicobacter infection		
subjects affected / exposed	2 / 95 (2.11%)	1 / 45 (2.22%)
occurrences (all)	2	1
Herpes virus infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	3	0
Herpes simplex		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Infected bite		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
lymphogranuloma venereum		
subjects affected / exposed	3 / 95 (3.16%)	1 / 45 (2.22%)
occurrences (all)	3	1
Malaria		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Oral infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Staphylococcal infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Nasal abscess		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Oral candidiasis		

subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Ear infection		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Pharyngeal chlamydia infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Tinea versicolour		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
pneumonia		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
COVID-19		
subjects affected / exposed	9 / 95 (9.47%)	3 / 45 (6.67%)
occurrences (all)	9	3
Pyelonephritis		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Respiratory tract infection		
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)
occurrences (all)	1	0
Sinusitis		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)
occurrences (all)	1	1
Syphilis		
alternative dictionary used: MedDRA 24		
subjects affected / exposed	6 / 95 (6.32%)	2 / 45 (4.44%)
occurrences (all)	8	2
Tooth abscess		
alternative dictionary used: MedDRA 24		

subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Upper respiratory tract infection			
subjects affected / exposed	4 / 95 (4.21%)	1 / 45 (2.22%)	
occurrences (all)	4	1	
Urinary tract infection			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	6 / 95 (6.32%)	2 / 45 (4.44%)	
occurrences (all)	7	3	
Vaginal infection			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Viral infection			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Herpes zoster			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Suspected COVID-19			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Onychomycosis			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	3 / 95 (3.16%)	0 / 45 (0.00%)	
occurrences (all)	3	0	
Cellulitis			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Gout			
alternative dictionary used: MedDRA 24			



subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	2	
Hypertriglyceridaemia			
subjects affected / exposed	0 / 95 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Hypocalcaemia			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Increased appetite			
subjects affected / exposed	1 / 95 (1.05%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Vitamin D deficiency			
subjects affected / exposed	6 / 95 (6.32%)	0 / 45 (0.00%)	
occurrences (all)	6	0	
Diabetes mellitus			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	0 / 95 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Hypophosphataemia			
alternative dictionary used: MedDRA 24			
subjects affected / exposed	1 / 95 (1.05%)	1 / 45 (2.22%)	
occurrences (all)	1	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 January 2021	Global amendment to update protocol V3.0 to V5.0

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/38417976>